Thyroid malignancies in survivors of Hodgkin lymphoma

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):636-41. doi: 10.1016/j.ijrobp.2013.11.237.

Abstract

Purpose: To quantify the incidence of thyroid cancer after Hodgkin lymphoma (HL) and determine disease characteristics, risk factors, and treatment outcomes.

Methods and materials: Thyroid cancer cases were retrospectively identified from a multi-institutional database of 1981 HL patients treated between 1969 and 2008. Thyroid cancer risk factors were evaluated by a Poisson regression model.

Results: With a median follow-up duration of 14.3 years (range, 0-41.2 years), 28 patients (1.4%) developed a thyroid malignancy. The overall incidence rate (expressed as the number of cases per 10,000 person-years) and 10-year cumulative incidence of thyroid cancer were 9.6 and 0.26%, respectively. There were no observed cases of thyroid malignancy in patients who received neck irradiation for HL after age 35 years. Age <20 years at HL diagnosis and female sex were significantly associated with thyroid cancer. The incidence rates of females aged <20 at HL diagnosis in the first 10 years, ≥10 years, ≥15 years, and ≥20 years after treatment were 5, 31, 61, and 75 cases per 10,000 person-years of follow-up, respectively. At a median follow-up of 3.5 years after the thyroid cancer diagnosis, 26 patients (93%) were alive without disease, 1 (4%) was alive with metastatic disease, and 1 (4%) died of metastatic disease, at 6 and 3.6 years after the thyroid cancer diagnosis, respectively.

Conclusions: Although HL survivors have an increased risk for thyroid cancer, the overall incidence is low. Routine thyroid cancer screening may benefit females treated at a young age and ≥10 years from HL treatment owing to their higher risk, which increases over time.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / therapeutic use
  • Child
  • Child, Preschool
  • Dacarbazine / therapeutic use
  • Databases, Factual
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Doxorubicin / therapeutic use
  • Female
  • Gemcitabine
  • Hodgkin Disease / pathology
  • Hodgkin Disease / therapy*
  • Humans
  • Male
  • Mechlorethamine / administration & dosage
  • Middle Aged
  • Neoplasms, Second Primary / epidemiology*
  • Neoplasms, Second Primary / pathology
  • Neoplasms, Second Primary / therapy
  • Poisson Distribution
  • Prednisone / administration & dosage
  • Procarbazine / administration & dosage
  • Radiotherapy Dosage
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Sex Factors
  • Survivors / statistics & numerical data*
  • Thyroid Neoplasms / epidemiology*
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / therapy
  • Vinblastine / therapeutic use
  • Vincristine / administration & dosage
  • Young Adult

Substances

  • Deoxycytidine
  • Bleomycin
  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Vinblastine
  • Dacarbazine
  • Doxorubicin
  • Prednisone
  • Gemcitabine

Supplementary concepts

  • ABVD protocol
  • MOPP protocol